Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)

Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for systemic treatment. Objectives This study evaluated the achievemen...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, the BRIGHT Study Group
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2023-12-01
Saila:	JEADV Clinical Practice
Gaiak:	brodalumab effectiveness observational psoriasis real‐world
Sarrera elektronikoa:	https://doi.org/10.1002/jvc2.204
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!